477 related articles for article (PubMed ID: 28596947)
1. Molecular mechanisms of hypoxia in cancer.
Challapalli A; Carroll L; Aboagye EO
Clin Transl Imaging; 2017; 5(3):225-253. PubMed ID: 28596947
[TBL] [Abstract][Full Text] [Related]
2. Imaging tumour hypoxia with positron emission tomography.
Fleming IN; Manavaki R; Blower PJ; West C; Williams KJ; Harris AL; Domarkas J; Lord S; Baldry C; Gilbert FJ
Br J Cancer; 2015 Jan; 112(2):238-50. PubMed ID: 25514380
[TBL] [Abstract][Full Text] [Related]
3. Molecular imaging of hypoxia.
Krohn KA; Link JM; Mason RP
J Nucl Med; 2008 Jun; 49 Suppl 2():129S-48S. PubMed ID: 18523070
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Molecular imaging of hypoxia with radiolabelled agents.
Mees G; Dierckx R; Vangestel C; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1674-86. PubMed ID: 19565239
[TBL] [Abstract][Full Text] [Related]
6. Imaging of hypoxia using PET and MRI.
Gaertner FC; Souvatzoglou M; Brix G; Beer AJ
Curr Pharm Biotechnol; 2012 Mar; 13(4):552-70. PubMed ID: 22214501
[TBL] [Abstract][Full Text] [Related]
7. Cherenkov luminescence imaging is a fast and relevant preclinical tool to assess tumour hypoxia in vivo.
Desvaux E; Courteau A; Bellaye PS; Guillemin M; Drouet C; Walker P; Collin B; Decréau RA
EJNMMI Res; 2018 Dec; 8(1):111. PubMed ID: 30574662
[TBL] [Abstract][Full Text] [Related]
8. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.
Bleeker G; Tytgat GA; Adam JA; Caron HN; Kremer LC; Hooft L; van Dalen EC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009263. PubMed ID: 26417712
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography to assess hypoxia and perfusion in lung cancer.
Verwer EE; Boellaard R; van der Veldt AA
World J Clin Oncol; 2014 Dec; 5(5):824-44. PubMed ID: 25493221
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.
van Elmpt W; Zegers CML; Reymen B; Even AJG; Dingemans AC; Oellers M; Wildberger JE; Mottaghy FM; Das M; Troost EGC; Lambin P
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):240-248. PubMed ID: 26338178
[TBL] [Abstract][Full Text] [Related]
11. Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET.
Huang Y; Fan J; Li Y; Fu S; Chen Y; Wu J
Front Oncol; 2021; 11():731503. PubMed ID: 34557414
[TBL] [Abstract][Full Text] [Related]
12. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling.
Bowen SR; van der Kogel AJ; Nordsmark M; Bentzen SM; Jeraj R
Nucl Med Biol; 2011 Aug; 38(6):771-80. PubMed ID: 21843774
[TBL] [Abstract][Full Text] [Related]
13. Imaging of brain oxygenation with magnetic resonance imaging: A validation with positron emission tomography in the healthy and tumoural brain.
Valable S; Corroyer-Dulmont A; Chakhoyan A; Durand L; Toutain J; Divoux D; Barré L; MacKenzie ET; Petit E; Bernaudin M; Touzani O; Barbier EL
J Cereb Blood Flow Metab; 2017 Jul; 37(7):2584-2597. PubMed ID: 27702880
[TBL] [Abstract][Full Text] [Related]
14. The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours.
Quartuccio N; Asselin MC
Curr Med Chem; 2018; 25(26):3074-3095. PubMed ID: 29149829
[TBL] [Abstract][Full Text] [Related]
15. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
16. Imaging hypoxia in tumours with advanced MRI.
Price JM; Robinson SP; Koh DM
Q J Nucl Med Mol Imaging; 2013 Sep; 57(3):257-70. PubMed ID: 24045622
[TBL] [Abstract][Full Text] [Related]
17. Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI.
O'Connor JPB; Robinson SP; Waterton JC
Br J Radiol; 2019 Mar; 92(1095):20180642. PubMed ID: 30272998
[TBL] [Abstract][Full Text] [Related]
18. PET and PET/CT studies of tumor tissue oxygenation.
Krause BJ; Beck R; Souvatzoglou M; Piert M
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):28-43. PubMed ID: 16557202
[TBL] [Abstract][Full Text] [Related]
19. Update of the role of PET/CT and PET/MRI in the management of patients with cervical cancer.
Khiewvan B; Torigian DA; Emamzadehfard S; Paydary K; Salavati A; Houshmand S; Shamchi SP; Werner TJ; Aydin A; Roy SG; Alavi A; Kumar R
Hell J Nucl Med; 2016; 19(3):254-268. PubMed ID: 27824966
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
[TBL] [
